MALVERN, Pa. -- Frontage Laboratories (#), a leading high quality provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry, announced today it has acquired a significant equity interest in Advanced Biomedical Research, Inc. (ABR) (#), an international, full service CRO. With the completion of this initial phase acquisition, the combined resources of Frontage and ABR offer unparalleled formulation develop...